{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Sacramento&page=10&state=California", "query": { "state": "California", "city": "Sacramento", "page": 10 }, "page_size": 10 }, "pagination": { "page": 10, "page_size": 10, "total_count": 5545, "total_pages": 555, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Sacramento&page=11&state=California&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Sacramento&page=9&state=California&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-25T04:55:22.386Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05642325", "title": "Vamikibart in Participants With Uveitic Macular Edema", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Uveitic Macular Edema" ], "interventions": [ { "name": "Vamikibart", "type": "DRUG" }, { "name": "Sham", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 256, "start_date": "2023-03-23", "completion_date": "2025-12-24", "has_results": false, "last_update_posted_date": "2026-04-17", "last_synced_at": "2026-10-25T04:55:22.386Z", "location_count": 23, "location_summary": "Phoenix, Arizona • Sun City, Arizona • Fullerton, California + 19 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Fullerton", "state": "California" }, { "city": "Mountain View", "state": "California" }, { "city": "Pasadena", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05642325" }, { "nct_id": "NCT03703882", "title": "Phase III Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Muscular Dystrophy, Duchenne" ], "interventions": [ { "name": "Edasalonexent", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Catabasis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "7 Years", "sex": "MALE", "summary": "4 Years to 7 Years · Male only" }, "enrollment_count": 131, "start_date": "2018-10-02", "completion_date": "2020-09-22", "has_results": true, "last_update_posted_date": "2022-06-21", "last_synced_at": "2026-10-25T04:55:22.386Z", "location_count": 24, "location_summary": "Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 20 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03703882" }, { "nct_id": "NCT00006462", "title": "Gemcitabine in Treating Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "gemcitabine hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 32, "start_date": "2001-04", "completion_date": "2006-09", "has_results": false, "last_update_posted_date": "2014-02-20", "last_synced_at": "2026-10-25T04:55:22.386Z", "location_count": 197, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 149 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006462" }, { "nct_id": "NCT06561386", "title": "A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Relatlimab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1000, "start_date": "2024-10-07", "completion_date": "2032-08-04", "has_results": false, "last_update_posted_date": "2026-10-23", "last_synced_at": "2026-10-25T04:55:22.386Z", "location_count": 58, "location_summary": "Mobile, Alabama • Tucson, Arizona • Los Angeles, California + 53 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06561386" }, { "nct_id": "NCT01185288", "title": "A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Adalimumab", "type": "BIOLOGICAL" }, { "name": "Methotrexate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "AbbVie (prior sponsor, Abbott)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 309, "start_date": "2010-09", "completion_date": "2013-01", "has_results": true, "last_update_posted_date": "2014-03-18", "last_synced_at": "2026-10-25T04:55:22.386Z", "location_count": 46, "location_summary": "Huntsville, Alabama • Tuscaloosa, Alabama • Mesa, Arizona + 40 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01185288" }, { "nct_id": "NCT07532603", "title": "A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Lichen Planopilaris" ], "interventions": [ { "name": "Oral Brepocitinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Priovant Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 342, "start_date": "2026-03-19", "completion_date": "2029-07-31", "has_results": false, "last_update_posted_date": "2026-07-08", "last_synced_at": "2026-10-25T04:55:22.386Z", "location_count": 47, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 42 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Irvine", "state": "California" }, { "city": "Oakland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07532603" }, { "nct_id": "NCT00823368", "title": "Biomarker Testing and DNA Collection in Subjects Participating in Protocol 22001", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Fragile X Syndrome" ], "interventions": [ { "name": "STX209", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seaside Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "6 Years to 40 Years" }, "enrollment_count": null, "start_date": "2009-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-07-31", "last_synced_at": "2026-10-25T04:55:22.386Z", "location_count": 11, "location_summary": "Phoenix, Arizona • Los Angeles, California • Sacramento, California + 8 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00823368" }, { "nct_id": "NCT01979497", "title": "Adhesive Strips in Dermatologic Surgery: Is Cosmetic Appearance Improved?", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Subjects Undergoing Surgical Procedure of the Skin" ], "interventions": [ { "name": "Suture with Adhesive Stripping", "type": "PROCEDURE" }, { "name": "Suture without Adhesive Stripping", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "University of California, Davis", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2013-08", "completion_date": "2014-06", "has_results": false, "last_update_posted_date": "2015-04-16", "last_synced_at": "2026-10-25T04:55:22.386Z", "location_count": 1, "location_summary": "Sacramento, California", "locations": [ { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01979497" }, { "nct_id": "NCT05610280", "title": "A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypertriglyceridemia", "Cardiovascular Diseases", "Atherosclerosis" ], "interventions": [ { "name": "Olezarsen", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ionis Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1478, "start_date": "2022-11-21", "completion_date": "2025-06-09", "has_results": false, "last_update_posted_date": "2026-02-10", "last_synced_at": "2026-10-25T04:55:22.386Z", "location_count": 68, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Beverly Hills, California + 54 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Huntington Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05610280" }, { "nct_id": "NCT01031173", "title": "Treatment Protocol of Replagal for Patients With Fabry Disease", "overall_status": "NO_LONGER_AVAILABLE", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Fabry Disease" ], "interventions": [ { "name": "agalsidase alfa", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2021-05-24", "last_synced_at": "2026-10-25T04:55:22.386Z", "location_count": 25, "location_summary": "Tucson, Arizona • La Jolla, California • Los Angeles, California + 21 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01031173" } ] }